Lower up-front payments for startups
The boom in biotech has had multiple impacts on early development companies. The lack of funding has forced many to tighten their belts, and...
Point-of-Care in the spotlight at Cardiac Markers Dialogue Meeting
Prolight Diagnostics recently participated at the 2024 Cardiac Markers Dialogue Meeting in Glasgow, UK. This meeting brought together leading researchers and healthcare professionals specializing...
PHI accelerates growth with record order
Phase Holographic Imaging recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive...
SynAct Pharma’s Chairman: ”We are confident we have the right strategy”
SynAct Pharma’s Capital Markets Day provided detailed information regarding the revised strategy for its lead asset, resomelagon. The company focuses on the phase IIb...
BiBB comments on the growing interest in EndoDrill GI
Intensive work is underway to get EndoDrill GI out to European and US clinics. BiBBInstruments recently participated in the seventh edition of the Nordic...
Lipum approaches the finish line in the study – last patient...
Lipum has recruited all rheumatoid arthritis patients for the final stage of its phase I study with SOL-116. With a 90-day follow-up period remaining,...
CombiGene’s CEO: “I am looking forward to meeting more potential partners”
CombiGene has a clear strategy to identify new, promising projects and academic research collaborations, but also to find a new development partner for the...
Mentice strengthens cardiology education in Germany through partnership
Mentice has entered into a strategic partnership with the German Society of Cardiology (DGK) and its interventional cardiology working group, AGIK, which focuses on...
WntResearch plummets after results
The initial results from the NeoFox clinical phase II study have arrived. The safety seems to be good, but unfortunately, Foxy-5 appears to have...
Saniona comments on the approval to initiate epilepsy study
Saniona has received approval to initiate a phase I multiple ascending dose and biomarker study in adults for SAN711, marking a key milestone toward...